eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

6/2021
vol. 13
 
Share:
Share:
more
 
 
abstract:
Original paper

Modified Houdek vault applicator for high-dose-rate brachytherapy: a technical report and case series

Revathy Krishnamurthy
1
,
Lavanya Gurram
2
,
Yogesh Ghadi
2
,
Dheera Aravindhan
2
,
Libin Scaria
2
,
Satish Kohle
2
,
Sudarshan Kadam
2
,
Supriya Chopra
1
,
Umesh Mahantshetty
1, 3

1.
Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
2.
Department of Medical Physics, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
3.
Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, India
J Contemp Brachytherapy 2021; 13, 6: 649–654
Online publish date: 2021/12/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Treatment of isolated post-surgical vault recurrence of cervical and endometrial cancers in previously unirradiated patients includes external beam radiotherapy (EBRT) ± concomitant chemotherapy, followed by brachytherapy (BT) boost. Supra-vaginal component of vault disease often requires interstitial BT for optimal dose coverage. We describe technical details and preliminary case series using modified Houdek vault applicator (MHVA) developed at our institution for limited intra-cavitary plus interstitial high-dose-rate (HDR) vault BT.

Material and methods
Nineteen patients with vaginal vault recurrences received BT boost with MHVA between October 2015 and May 2018. All underwent BT application and CT-based BT planning after completion of EBRT ± concomitant chemotherapy.

Results
Median EQD2 of BT dose in patients with carcinoma cervix recurrence (n = 15, / = 10) was 18.8 Gy, and in those with endometrial cancer recurrence was 22.08 Gy (n = 4, / = 4.5). Median total EQD2 was 68.8 Gy and 72.08 Gy, respectively. Mean 2 cc of bladder, rectum, and sigmoid EBRT + BT doses (EQD2, / = 3) were 65.38 Gy (±7.76), 63.37 Gy (±5.52), and 57.04 Gy (±4.45), respectively. At 6-8 weeks, 17 patients showed complete response (CR). With median follow-up of 20.5 months, 2-year overall survival was 95% (95% CI: 85.2-100.0%), and 2-year progression-free survival was 79.4% (95% CI: 61.0-97.8%). Late toxicities seen were grade 2 proctitis in 1 patient, grade 1 proctitis in 5, grade 2 urethritis in 1, grade 3 cystitis in 1, and recto-vaginal fistula in 1 patient (with disease controlled). Recurrence rate was 6.7 times higher in patients with post-EBRT disease greater than 10 mm (p = 0.01).

Conclusions
MHVA is a simple solution for intra-cavitary and interstitial HDR-BT boost in isolated vault cancers post-surgery, achieving acceptable dosimetric parameters. Preliminary clinical outcomes and late toxicities are satisfactory.

keywords:

vaginal vault, brachytherapy, intra-cavity radiotherapy, interstitial radiotherapy

 
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.